Diabetic macular oedema commercial dynamics are being reshaped by the long-duration anti-VEGF class

Reading the signal

Diabetic macular oedema (DME) is a leading cause of vision loss in patients with diabetic retinopathy. The therapeutic landscape has evolved:

• Anti-VEGF class: Ranibizumab, aflibercept, brolucizumab, faricimab. The dominant first-line class with response rates and visual-acuity preservation across pivotal trials
• High-dose aflibercept: New formulation extending dosing intervals
• Faricimab: Anti-VEGF/Ang-2 bispecific with extended dosing intervals
• Steroid implants: Dexamethasone (Ozurdex) and fluocinolone (Iluvien) for specific patient profiles
• Anti-VEGF biosimilars: Increasingly part of the commercial conversation

The long-duration class (faricimab, high-dose aflibercept) has emerged as commercially distinctive based on the extended dosing intervals, with implications:

• Reduced patient burden: Fewer injections per year translates to materially better quality-of-life and adherence outcomes
• Reduced clinic burden: Fewer injection visits per patient per year frees clinic capacity, which is structurally constrained
• Repricing dynamics: The patient-burden-reduction value proposition is being weighed against the biosimilar-floor pricing for the established class

Commercial implications

For sponsors of DME and adjacent retinal therapy:

1. Dosing-interval differentiation is now the decisive commercial axis in DME, more so than absolute efficacy differentiation between assets
2. The anti-VEGF biosimilar dynamic affects the long-duration value proposition. Net pricing for biosimilars shapes how much the long-duration premium can sustain
3. Steroid implants are being repositioned for specific patient profiles where the steroid mechanism offers complementary or alternative benefit; the niche is real but commercially narrower than the long-duration anti-VEGF class

What we are watching

• Real-world dosing-interval data for the long-duration class and the rate of clinic uptake
• Biosimilar pricing dynamics in DME and the rate of net-pricing pressure on the long-duration premium
• Late-stage pipeline including extended-duration formulations, gene-therapy approaches, and novel mechanism programs in DME